This is a news story, published by Semafor, that relates primarily to Rift Valley news.
For more Rift Valley news, you can click here:
more Rift Valley newsFor more vaccine development news, you can click here:
more vaccine development newsFor more news from Semafor, you can click here:
more news from SemaforOtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like this article about vaccine development, you might also like this article about
African biotech company Afrigen. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest gene therapy treatments news, groundbreaking gene therapy treatments news, news about vaccine development, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
gene therapySemafor
•84% Informative
South African biotech company Afrigen is collaborating with a Nobel Prize -winning scientist to develop groundbreaking gene therapy treatments that target diseases that have plagued Africa for decades .
The company is developing a new generation of mRNA vaccines for a range of diseases including HIV, tuberculosis (TB), Rift Valley fever, and gonorrhea.
It has a mandate to share technology and expertise with vaccine producers and research institutions.
He said investment in training programs to develop local expertise in mRNA technology would be âessentialâ for it to be taken up, adding that âharmonizing and simplifying regulatory frameworks across the continentâ would expedite the approval and implementation of new technologies. Boum told Semafor Africa the widespread deployment of techniques like mRNA technology âwill take yearsâ because it would only follow the building of human capacity and the sharing of technology, which would require investment..
VR Score
89
Informative language
92
Neutral language
21
Article tone
formal
Language
English
Language complexity
65
Offensive language
not offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
2
Source diversity
2
Affiliate links
no affiliate links